FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not Worried – ValueWalk Premium
Endo Pharmaceuticals

FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not Worried

The Federal Trade Commission said Thursday that Endo Pharmaceuticals violated federal antitrust laws by paying Impax Laboratories and Watson Laboratories to delay launching their approved generic versions. The latest case is the first by the commission that challenges an agreement not to market an authorized generic.

FTC claims "pay-for-delay" agreements cost consumers billions


This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click chat.

Saved Articles

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

What’s missing today for many investors is real, straightforward advice.

Especially when it comes to Value Investing and Hedge Funds. 💵

That’s what makes ValueWalk Premium different. Some would say we’re “unusual.”

Our subscribers look forward to clear, easy-to-understand information they can act on.

Sign up for  today for only a few dollars a day and get a 3 day no obligation trial with a targeted 20% discount coupon code.

Cancel anytime during trial and you are never charged.

Limited time offer: For first 50 subscribers